New Jersey A913 authorizes medical cannabis for treating sickle cell anemia.
New Jersey A913 amends existing law to include sickle cell anemia as a qualifying medical condition for the medical use of cannabis. Sickle cell anemia is an inherited blood disorder characterized by chronic anemia and periodic episodes of pain. The bill allows patients with this condition to use medical cannabis to treat or alleviate their symptoms. The medical use of cannabis is already authorized for several other conditions, including seizure disorders, chronic pain, and cancer. The bill takes effect immediately upon enactment.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.